Statins play a vital role in the prevention of atherosclerotic cardiovascular complications and statin therapy continues to be cornerstone in treating patients with dyslipidemia. However, statin-associated myopathy affects up to 10%-12% of patients which can range from myalgia to a severe muscle weakness and rhabdomyolysis. Histopathological features and neuroimaging changes of statin-induced weakness are not studied so often. We present a case of 65-year-old female patient who presented with quadriparesis and myalgia-induced by statins; and we tried to find histopathological and electromyographic changes associated with statin-induced myopathy.
INTRODUCTION
Statins consistently have been shown to reduce cardiovascularrelated mortality and morbidity through the reduction of low-density lipoproteins leading to a trend of increased statin usage. Statin-induced myopathy is an established fact but histopathological and electromyographic features are not studied so often. Hence, we studied this case presenting with myalgia and muscle weakness, clinically diagnosed as statin-induced myopathy and provided the histopathological and electromyographic evidence for the same. Thus, we want to prove that histopathological and electromyographic study can be great tools in early diagnosis and management of statin-induced myopathy.
CASE REPORT
A 62-year-old female patient, as per her history, was apparently normal until she started complaining of muscle pain followed by weakness in upper limbs. There was difficulty in combing hair and eating food followed by difficulty in getting up from sitting position and in 2 days, it progressed to quadriparesis. The patient was a known case of dilated cardiomyopathy (DCM) with left ventricular dysfunction, on regular treatment for the past 10 years.
Recently, on her follow-up visit 1 month back, statins were up-titrated and changed to rosuvastatin 20 MG due to deranged lipid profile. There was no history of similar episodes of any muscle weakness. The patient presented on day 2 after developing quadriparesis. On nervous system examination, higher mental function was normal, motor examination showed hypotonia with an initial power of 2/5 in both upper and lower limbs, deep tendon reflexes were present, plantar bilateral flexor response, and sensory examination were normal. Cardiovascular system and other systemic examination were normal except signs of DCM. The patient neurological evaluation was done by a neurologist and possibility of drug-induced versus polymyositis versus metabolic was kept. Blood tests were sent in view to rule out rhabdomyolysis, metabolic derangement, thyroid, and other autoimmune disorders [ Table 1 ]. All tests were normal except a marked rise in creatinine phosphokinase (CPK) suggestive of muscle injury.
Electromyography was done on the 5 th day after admission. Sample muscles used were deltoid, quadriceps, biceps, and tibialis anterior. Short duration, low amplitude, and polyphasic motor unit action potentials (MUAPs) were noted in deltoid and quadriceps which are suggestive of myopathy [ Figure 1 ].
Histopathological evaluation done from vastus medialis of right thigh showed aggregation of lymphocytes, phagocytes, and vacuolated myocytes suggestive of myositis [ Figure 2 ].
Patient's statins were stopped, and the patient recovered slowly and by day 10 she had only proximal muscle weakness and myalgia at the time of discharge. After 1 and 3 months follow-up, patient was found to have no weakness and myalgia.
DISCUSSION
Statins play a major role in both primary and secondary prevention of coronary artery disease. Statins are considered cornerstone treatment of coronary artery disease by most of the clinical physicians. Statins are very well tolerated by most patients; however, 10%-12% of patients develop muscle-related adverse effects. [1] A systematic review by Law and Rudnicka included 21 clinical trials providing 18,000 person-years of follow-up in patients treated with statins or placebo and were found to have estimated rates of statin-related myalgia (defined as a minor muscle pain), myopathy (defined as muscle pain, tenderness, or weakness sufficient to consult a physician or stop taking a statin) and rhabdomyolysis as 190, 5 and 1.6 patients/100,000 person-years, respectively. [2] CPK elevation has become the primary marker for ongoing muscle cell death and destruction. An elevation of CPK is the best indicator of statin-induced myopathy. As we know that elevated CPK levels can be seen in various other cases, so sometimes, it becomes difficult to know the exact cause of weakness, especially in old age. In cases of weakness, localization of the disorder is a major aim. In these patients, electro-diagnostic studies can be useful to localize the disorder to the motor neuron/ axon, neuromuscular junction or the muscle. In our case, we found that on electromyography there is short duration, low amplitude and polyphasic MUAPs. These small-amplitude, short-duration MUAP are the electromyographic hallmarks of myopathy so often referred to as "myopathic" and can be seen in a variety of myopathy including toxic/necrotic myopathy. [3] Hence, these types of motor unit potentials are characteristic of myopathic disorder which helps to rule out other disorders associated with the neuronal or axonal system. Histopathological examination showed aggregation of lymphocytes, associated with phagocytosis and vacuolated myocytes. While checking literature, we came across a study done by Carvalho et al. and others in 2004 in which eight patients presenting with statin induce myopathy were studied. They did muscle biopsy of six patients and found variation in fiber's diameter in all cases, necrosis of fibers in five cases, inflammatory infiltration in one case, the presence of vacuolated fiber in one patient and ragged-red fibers in three patients. [4] Hence, in conclusion, we can say that electromyography and histopathological examination can be helpful tools in diagnosing statin induce myopathy along with blood examination and clinical suspicion.
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